BARCELONA, Spain, March 14, 2026
New real-world evidence presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) highlights the sustained performance of Eversense 365, the world’s first implantable continuous glucose monitoring (CGM) system designed to last for a full year. The findings demonstrate strong patient adherence, reliable glucose monitoring accuracy, and improved glycemic outcomes throughout the entire one-year wear period, marking a major advancement in diabetes management technology.
Real-World Evidence Confirms Long-Term CGM Performance
The real-world study evaluated 5,059 Eversense 365 CGM sensors used by patients in the United States, analyzing how the system performed in everyday diabetes care settings. Results revealed consistent performance and sustained accuracy over the full 365-day period, supporting the system’s ability to deliver reliable glucose monitoring for people living with diabetes.
Patients using the system showed an average transmitter wear time of 93.8%, indicating strong adherence to the device. Importantly, performance metrics remained consistent between the first six months and the second six months of use, demonstrating that the single implanted sensor can maintain high reliability across its entire lifespan.
Researchers also reported positive glucometric outcomes, including a mean Glucose Management Indicator (GMI) of 7.14% and an average Time in Range (TIR) of 66%, both widely recognized indicators of effective glucose control. These findings suggest that long-term CGM technology may help patients better manage blood glucose levels while reducing daily monitoring burdens.
Advertisement
Strong Hypoglycemia Outcomes and Safety Benefits
The analysis further showed that more than 75% of users achieved hypoglycemia targets, highlighting the device’s accuracy in detecting low blood glucose levels — a critical factor for patient safety. Accurate detection of hypoglycemia can significantly reduce the risk of dangerous glucose events and improve clinical decision-making for both patients and healthcare providers.
Unlike traditional CGM systems that require frequent sensor replacement every 7 to 14 days, Eversense 365 offers continuous monitoring for up to one full year using a single implantable sensor. This approach can reduce interruptions in glucose monitoring and improve overall patient convenience, enabling people with diabetes to focus more on disease management rather than device maintenance.
The technology was approved by the U.S. Food and Drug Administration (FDA) in September 2024 and later received CE Mark approval in Europe in early 2026, paving the way for expansion into additional international markets.
Improved Outcomes Across Different Age Groups
The study also evaluated device performance across different patient age groups and found positive glycemic outcomes in all demographics. However, older adults aged 65 and above showed particularly strong results, achieving a mean GMI of 6.99% and a Time in Range exceeding 70%, along with over 95% transmitter wear adherence.
Interestingly, young adults aged 18–25 also demonstrated strong engagement with the technology, with more than 90% average wear time and a mean GMI of 7.3%, suggesting that long-term CGM solutions may help improve glucose management even among populations traditionally associated with lower adherence rates.
Additionally, early analysis of the twiist™ automated insulin delivery (AID) system integrated with Eversense 365 showed promising results. In an initial group of approximately 120 users, the combination produced a mean GMI of 6.79% and a Time in Range of 77%, meeting international clinical targets for diabetes management.
Transforming Long-Term Diabetes Monitoring
Experts believe that implantable CGM systems like Eversense 365 represent a significant innovation in diabetes care, offering continuous, accurate glucose data for up to 12 months with minimal interruptions. By reducing the need for frequent sensor replacements and improving long-term monitoring reliability, this technology may help healthcare providers and patients make more informed treatment decisions and improve long-term metabolic outcomes.
With growing commercial adoption in the United States and upcoming launches in European markets including Germany, Italy, Spain, and Sweden, Eversense 365 could play a key role in advancing next-generation diabetes monitoring solutions worldwide.
Source: Senseonics press release
